Duodenal Infusion of Feces for Recurrent Clostridium difficile
To the Editor: Van Nood et al. (Jan. 31 issue) 1 found fecal microbiota therapy to be superior to vancomycin for the treatment of recurrent Clostridium difficile infection, but the results of their study should be interpreted with caution. Small, index trials such as this one are vulnerable to exagg...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2013-05, Vol.368 (22), p.2143-2145 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2145 |
|---|---|
| container_issue | 22 |
| container_start_page | 2143 |
| container_title | The New England journal of medicine |
| container_volume | 368 |
| creator | Van Schooneveld, Trevor C Gross, Alan Kalil, Andre C Hataye, Jason M Palmore, Tara N Powers, John H Ramsauer, Bernhard Lehrer, Steven van Nood, Els Dijkgraaf, Marcel G.W Keller, Josbert J |
| description | To the Editor:
Van Nood et al. (Jan. 31 issue)
1
found fecal microbiota therapy to be superior to vancomycin for the treatment of recurrent
Clostridium difficile
infection, but the results of their study should be interpreted with caution. Small, index trials such as this one are vulnerable to exaggerated treatment effects, and subsequent trials typically show decreased effects.
2
Even though the trial was randomized, the results may have been influenced by inequalities among the three treatment groups in terms of either the number of pretreatment recurrences of
C. difficile
infection or post-treatment exposure to an antimicrobial agent or proton-pump inhibitor . . . |
| doi_str_mv | 10.1056/NEJMc1303919 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1357494679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1357494439</sourcerecordid><originalsourceid>FETCH-LOGICAL-c605t-99761aa7d13c28e65a696ce90f3ed361fe4f0c29c66b3e7e8092f135962bc91a3</originalsourceid><addsrcrecordid>eNqN0s9LwzAUB_AgipvTm2cp6MGD1fxq2lwEmZtOpoLouWTpC2S0zUzag_-9lU4R8dB3eZcPX3i8L0LHBF8SnIirp9nDoyYMM0nkDhqThLGYcyx20RhjmsU8lWyEDkJY424Il_toRFlKMiKyMbq-bV0BtSqjRW3aYF0dORPNQUOIjPPRC-jWe6ibaFq60Hhb2LaKCmuM1baEQ7RnVBngaLsn6G0-e53ex8vnu8X0ZhlrgZMmljIVRKm0IEzTDESihBQaJDYMCiaIAW6wplILsWKQQoYlNYQlUtCVlkSxCTrvczfevbcQmryyQUNZqhpcG_LOplxy0d06kPIkHUzZ8FTKBlOcdfT0D1271nff6BWmXFDcqYteae9C8GDyjbeV8h85wflXB_LfHej4yTa0XVVQ_ODvp3fgrAdVFfIa1tX_OZ_bPrK1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1357024620</pqid></control><display><type>article</type><title>Duodenal Infusion of Feces for Recurrent Clostridium difficile</title><source>MEDLINE</source><source>New England Journal of Medicine Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><creator>Van Schooneveld, Trevor C ; Gross, Alan ; Kalil, Andre C ; Hataye, Jason M ; Palmore, Tara N ; Powers, John H ; Ramsauer, Bernhard ; Lehrer, Steven ; van Nood, Els ; Dijkgraaf, Marcel G.W ; Keller, Josbert J</creator><creatorcontrib>Van Schooneveld, Trevor C ; Gross, Alan ; Kalil, Andre C ; Hataye, Jason M ; Palmore, Tara N ; Powers, John H ; Ramsauer, Bernhard ; Lehrer, Steven ; van Nood, Els ; Dijkgraaf, Marcel G.W ; Keller, Josbert J</creatorcontrib><description>To the Editor:
Van Nood et al. (Jan. 31 issue)
1
found fecal microbiota therapy to be superior to vancomycin for the treatment of recurrent
Clostridium difficile
infection, but the results of their study should be interpreted with caution. Small, index trials such as this one are vulnerable to exaggerated treatment effects, and subsequent trials typically show decreased effects.
2
Even though the trial was randomized, the results may have been influenced by inequalities among the three treatment groups in terms of either the number of pretreatment recurrences of
C. difficile
infection or post-treatment exposure to an antimicrobial agent or proton-pump inhibitor . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1303919</identifier><identifier>PMID: 23718168</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Clostridium difficile ; Diarrhea - therapy ; Fecal microflora ; Feces ; Feces - microbiology ; Female ; Humans ; Male ; Microbiota ; Paullini ; Proton pump inhibitors ; Recurrent infection ; Vancomycin ; Vancomycin - therapeutic use</subject><ispartof>The New England journal of medicine, 2013-05, Vol.368 (22), p.2143-2145</ispartof><rights>Copyright © 2013 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c605t-99761aa7d13c28e65a696ce90f3ed361fe4f0c29c66b3e7e8092f135962bc91a3</citedby><cites>FETCH-LOGICAL-c605t-99761aa7d13c28e65a696ce90f3ed361fe4f0c29c66b3e7e8092f135962bc91a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1303919$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1357024620?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23718168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Schooneveld, Trevor C</creatorcontrib><creatorcontrib>Gross, Alan</creatorcontrib><creatorcontrib>Kalil, Andre C</creatorcontrib><creatorcontrib>Hataye, Jason M</creatorcontrib><creatorcontrib>Palmore, Tara N</creatorcontrib><creatorcontrib>Powers, John H</creatorcontrib><creatorcontrib>Ramsauer, Bernhard</creatorcontrib><creatorcontrib>Lehrer, Steven</creatorcontrib><creatorcontrib>van Nood, Els</creatorcontrib><creatorcontrib>Dijkgraaf, Marcel G.W</creatorcontrib><creatorcontrib>Keller, Josbert J</creatorcontrib><title>Duodenal Infusion of Feces for Recurrent Clostridium difficile</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Van Nood et al. (Jan. 31 issue)
1
found fecal microbiota therapy to be superior to vancomycin for the treatment of recurrent
Clostridium difficile
infection, but the results of their study should be interpreted with caution. Small, index trials such as this one are vulnerable to exaggerated treatment effects, and subsequent trials typically show decreased effects.
2
Even though the trial was randomized, the results may have been influenced by inequalities among the three treatment groups in terms of either the number of pretreatment recurrences of
C. difficile
infection or post-treatment exposure to an antimicrobial agent or proton-pump inhibitor . . .</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Clostridium difficile</subject><subject>Diarrhea - therapy</subject><subject>Fecal microflora</subject><subject>Feces</subject><subject>Feces - microbiology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Microbiota</subject><subject>Paullini</subject><subject>Proton pump inhibitors</subject><subject>Recurrent infection</subject><subject>Vancomycin</subject><subject>Vancomycin - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0s9LwzAUB_AgipvTm2cp6MGD1fxq2lwEmZtOpoLouWTpC2S0zUzag_-9lU4R8dB3eZcPX3i8L0LHBF8SnIirp9nDoyYMM0nkDhqThLGYcyx20RhjmsU8lWyEDkJY424Il_toRFlKMiKyMbq-bV0BtSqjRW3aYF0dORPNQUOIjPPRC-jWe6ibaFq60Hhb2LaKCmuM1baEQ7RnVBngaLsn6G0-e53ex8vnu8X0ZhlrgZMmljIVRKm0IEzTDESihBQaJDYMCiaIAW6wplILsWKQQoYlNYQlUtCVlkSxCTrvczfevbcQmryyQUNZqhpcG_LOplxy0d06kPIkHUzZ8FTKBlOcdfT0D1271nff6BWmXFDcqYteae9C8GDyjbeV8h85wflXB_LfHej4yTa0XVVQ_ODvp3fgrAdVFfIa1tX_OZ_bPrK1</recordid><startdate>20130530</startdate><enddate>20130530</enddate><creator>Van Schooneveld, Trevor C</creator><creator>Gross, Alan</creator><creator>Kalil, Andre C</creator><creator>Hataye, Jason M</creator><creator>Palmore, Tara N</creator><creator>Powers, John H</creator><creator>Ramsauer, Bernhard</creator><creator>Lehrer, Steven</creator><creator>van Nood, Els</creator><creator>Dijkgraaf, Marcel G.W</creator><creator>Keller, Josbert J</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130530</creationdate><title>Duodenal Infusion of Feces for Recurrent Clostridium difficile</title><author>Van Schooneveld, Trevor C ; Gross, Alan ; Kalil, Andre C ; Hataye, Jason M ; Palmore, Tara N ; Powers, John H ; Ramsauer, Bernhard ; Lehrer, Steven ; van Nood, Els ; Dijkgraaf, Marcel G.W ; Keller, Josbert J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c605t-99761aa7d13c28e65a696ce90f3ed361fe4f0c29c66b3e7e8092f135962bc91a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Clostridium difficile</topic><topic>Diarrhea - therapy</topic><topic>Fecal microflora</topic><topic>Feces</topic><topic>Feces - microbiology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Microbiota</topic><topic>Paullini</topic><topic>Proton pump inhibitors</topic><topic>Recurrent infection</topic><topic>Vancomycin</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Schooneveld, Trevor C</creatorcontrib><creatorcontrib>Gross, Alan</creatorcontrib><creatorcontrib>Kalil, Andre C</creatorcontrib><creatorcontrib>Hataye, Jason M</creatorcontrib><creatorcontrib>Palmore, Tara N</creatorcontrib><creatorcontrib>Powers, John H</creatorcontrib><creatorcontrib>Ramsauer, Bernhard</creatorcontrib><creatorcontrib>Lehrer, Steven</creatorcontrib><creatorcontrib>van Nood, Els</creatorcontrib><creatorcontrib>Dijkgraaf, Marcel G.W</creatorcontrib><creatorcontrib>Keller, Josbert J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Schooneveld, Trevor C</au><au>Gross, Alan</au><au>Kalil, Andre C</au><au>Hataye, Jason M</au><au>Palmore, Tara N</au><au>Powers, John H</au><au>Ramsauer, Bernhard</au><au>Lehrer, Steven</au><au>van Nood, Els</au><au>Dijkgraaf, Marcel G.W</au><au>Keller, Josbert J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Duodenal Infusion of Feces for Recurrent Clostridium difficile</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2013-05-30</date><risdate>2013</risdate><volume>368</volume><issue>22</issue><spage>2143</spage><epage>2145</epage><pages>2143-2145</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Van Nood et al. (Jan. 31 issue)
1
found fecal microbiota therapy to be superior to vancomycin for the treatment of recurrent
Clostridium difficile
infection, but the results of their study should be interpreted with caution. Small, index trials such as this one are vulnerable to exaggerated treatment effects, and subsequent trials typically show decreased effects.
2
Even though the trial was randomized, the results may have been influenced by inequalities among the three treatment groups in terms of either the number of pretreatment recurrences of
C. difficile
infection or post-treatment exposure to an antimicrobial agent or proton-pump inhibitor . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>23718168</pmid><doi>10.1056/NEJMc1303919</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2013-05, Vol.368 (22), p.2143-2145 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1357494679 |
| source | MEDLINE; New England Journal of Medicine Current; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland |
| subjects | Anti-Bacterial Agents - therapeutic use Clostridium difficile Diarrhea - therapy Fecal microflora Feces Feces - microbiology Female Humans Male Microbiota Paullini Proton pump inhibitors Recurrent infection Vancomycin Vancomycin - therapeutic use |
| title | Duodenal Infusion of Feces for Recurrent Clostridium difficile |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A08%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Duodenal%20Infusion%20of%20Feces%20for%20Recurrent%20Clostridium%20difficile&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Van%20Schooneveld,%20Trevor%20C&rft.date=2013-05-30&rft.volume=368&rft.issue=22&rft.spage=2143&rft.epage=2145&rft.pages=2143-2145&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1303919&rft_dat=%3Cproquest_cross%3E1357494439%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1357024620&rft_id=info:pmid/23718168&rfr_iscdi=true |